Replimune (REPL) Cash & Equivalents (2018 - 2025)

Replimune has disclosed Cash & Equivalents across 8 years of filings, most recently posting $123.0 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $123.0 million, down 28.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $123.0 million (down 28.62% YoY), and the FY2025 annual result was $111.1 million, up 49.24% from the prior year.
• Cash & Equivalents came in at $123.0 million for Q4 2025 at Replimune, up from $102.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $206.7 million in Q4 2022 to a low of $74.5 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $112.9 million (2022), against an average of $124.9 million.
• Peak annual rise in Cash & Equivalents reached 397.16% in 2021, while the deepest fall reached 59.23% in 2021.
• Replimune's Cash & Equivalents stood at $132.3 million in 2021, then jumped by 56.24% to $206.7 million in 2022, then slumped by 52.74% to $97.7 million in 2023, then surged by 76.35% to $172.2 million in 2024, then declined by 28.62% to $123.0 million in 2025.
• The last three Cash & Equivalents figures came in at $123.0 million (Q4 2025), $102.3 million (Q3 2025), and $97.4 million (Q2 2025), per Business Quant data.